The Covid Open Vaccine International Platform for Safety

and LONG COVID

The mission of COVIPS Long COVID is to scientifically measure and publish data on the specific effect of COVID Vaccines.

Aboard the GLOBAL CHALLENGER, cruising safely in UK waters, Long COVID UK volunteers will participate in a randomised controlled trial with the leading UK approved COVID vaccines.

Over a Third of COVID-19 Patients Diagnosed with at Least One Long-COVID Symptom

Researchers at the University of Oxford, the National Institute for Health Research (NIHR) and the Oxford Health Biomedical Research Centre (BRC) have studied the health records of 273,618 people recovering from COVID-19 in the US.

Anxiety or depression was the most common of nine core long Covid symptoms reported among 273,618 people recovering from coronavirus in the US:

  • Anxiety/depression 15%
  • Abnormal breathing 8%
  • Abdominal symptoms 8%
  • Chest/throat pain 6%
  • Fatigue 6%
  • Headache 5%
  • Cognitive problems (‘brain fog’) 4%
  • Myalgia (muscle pain) 1.5%
  • Other pain 7%

Source: Incidence, co-occurrence, and evolution of long-COVID features: A 6 month retrospective cohort study of 273,618 survivors of COVID-19 – PLOS Medicine.

DOI: 10.1371/journal.pmed.1003773

  • This research used data from electronic health records of 273,618 patients diagnosed with COVID-19 and estimated the risk of having long-COVID features in the 6 months after a diagnosis of COVID-19. It compared the risk of long-COVID features in different groups within the population and also compared the risk to that after influenza.
  • The research found that over 1 in 3 patients had one or more features of long-COVID recorded between 3 and 6 months after a diagnosis of COVID-19. This was significantly higher than after influenza.
  • For 2 in 5 of the patients who had long-COVID features in the 3- to 6-month period, they had no record of any such feature in the previous 3 months.
  • The risk of long-COVID features was higher in patients who had more severe COVID-19 illness, and slightly higher among females and young adults. White and non-white patients were equally affected.

NIHR Academic Clinical Fellow, Dr Max Taquet, who led the analyses, University of Oxford, said:

‘The results confirm that a significant proportion of people, of all ages, can be affected by a range of symptoms and difficulties in the six months after COVID-19 infection. These data complement findings from self-report surveys, and show that clinicians are diagnosing patients with these symptoms. We need appropriately configured services to deal with the current and future clinical need.’

Professor Paul Harrison, who headed the study, Department of Psychiatry, University of Oxford, said:

‘Research of different kinds is urgently needed to understand why not everyone recovers rapidly and fully from COVID-19. We need to identify the mechanisms underlying the diverse symptoms that can affect survivors. This information will be essential if the long-term health consequences of COVID-19 are to be prevented or treated effectively.’